Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon *EGFR* Mutations
In advanced non-small cell lung cancer (NSCLC), epidermal growth factor receptor (*EGFR*) mutations are one of the most frequent oncogenic drivers. They confer a favorable prognosis and strongly predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Over the last decades, several *EGFR* gene...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2020-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2020.03.011 |